-
Mashup Score: 2OPTIMISMM: PVd for lenalidomide-refractory myeloma - 3 year(s) ago
Katja Weisel, MD, of the University Medical Center Hamburg-Eppendorf, Hamburg, Germany, shares updates from the OPTISMM trial (NCT01734928), a Phase…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 6The future myeloma treatment landscape - 3 year(s) ago
Jesús San Miguel, MD, PhD, University of Navarra Clinic, Pamplona, Spain, talks on the future of myeloma treatment, highlighting research…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Jesús San Miguel (@unav) shares his thoughts on the future of #Myeloma treatment ⭐Discussing precursor B-cells, the microenvironment, circulating plasma cells & resistance⭐ https://t.co/HHoUwezidx @Myeloma_Society #IMW2021 #IMW21 #MMsm #HemOnc #BloodCancerAwarenessMonth #BCAM
-
-
Mashup Score: 1MRD in myeloma: the FDA perspective - 3 year(s) ago
Hermann Einsele, MD, FRCP, of the University of Würzburg, Würzburg, Germany, and Heinz Ludwig, MD, of the Wilhelminen Cancer Research…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🩸MRD in #Myeloma Hermann Einsele (@Uni_WUE) & Heinz Ludwig discuss #MRD assessment for the treatment of myeloma, talking on the FDA perspective: https://t.co/aggyuVPsR1 @Myeloma_Society #IMW2021 #IMW21 #MultipleMyeloma #MMsm #HemOnc #mmMRD #CancelBloodCancer #BCAM
-
-
Mashup Score: 2Updates on ide-cel and cilta-cel for myeloma - 3 year(s) ago
Saad Usmani, MD, MBBS, MBA, of Levine Cancer Institute/Carolinas HealthCare System, Charlotte, NC, gives an overview of the latest updates…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Latest updates on the use of #CART for #Myeloma @szusmani of @LevineCancer discusses ide-cel and cilta-cel 👉https://t.co/1NSV0ZIyKI👈 @VJHemOnc @Myeloma_Society #IMW2021 #IMW21 #MultipleMyeloma #MMsm #HemOnc #BloodCancerAwarenessMonth #CancelBloodCancer #BCAM
-
-
Mashup Score: 1
Minimal residual disease–based consolidation therapy comprised of daratumumab, carfilzomib, lenalidomide, and dexamethasone was found to induce quick responses and unprecedented rates of MRD negativity in patients with newly diagnosed multiple myeloma.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
MRD–based consolidation therapy comprised of daratumumab, carfilzomib, lenalidomide, & dexamethasone was found to induce quick responses & unprecedented rates of MRD negativity in pts w/ newly diagnosed multiple myeloma. @ONealCancerUAB #IMW21 #mmsm https://t.co/1yiM36hfCN
-
-
Mashup Score: 1Elranatamab Alone or Plus Lenalidomide Shows Early Efficacy, Safety in Heavily Relapsed Myeloma - 3 year(s) ago
Elranatamab elicited encouraging responses with a manageable toxicity profile when used alone or in combination with lenalidomide in patients with relapsed/refractory multiple myeloma, with efficacy observed even in those who received prior BCMA-directed therapy or who were triple-class refractory, according to data from the phase 1 MagnetisMM-1 trial.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
According to data from the phase 1 MagnetisMM-1 trial, results showed that when elranatamab was administered at doses that were 215 μg/kg or higher, it induced an ORR of 70.0%, with a sCR/CR rate of 30.0%. @DholariaMD @VUMChealth #IMW21 #mmsm #oncology https://t.co/SFQeZYPf0v https://t.co/vpEkd1KsCh
-
-
Mashup Score: 1
Talquetamab, an off-the-shelf T-cell redirecting, GP3C5D-targeting agent, has continued to show promising clinical activity in patients with relapsed/refractory multiple myeloma, especially when given at the recommended phase 2 dose of 405 µg/kg weekly in subcutaneous formulation.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Talquetamab has continued to show promising clinical activity in patients with relapsed/refractory multiple myeloma, especially when given at the recommended phase 2 dose of 405 µg/kg weekly in subcutaneous formulation. #IMW21 #mmsm #oncology https://t.co/ggz9DZdd2Y
-
-
Mashup Score: 0The Multiple Myeloma Daily - 3 year(s) ago
A selection of articles, blog posts, videos and photos recommended by Robert Z. Orlowski
Source: paper.liCategories: Hem/Oncs, Latest HeadlinesTweet-
The latest The Multiple Myeloma Daily! https://t.co/mxDwGboCt7 Thanks to @smbenlazar #imw21 #myeloma
-
-
Mashup Score: 1
Minimal residual disease–based consolidation therapy comprised of daratumumab, carfilzomib, lenalidomide, and dexamethasone was found to induce quick responses and unprecedented rates of MRD negativity in patients with newly diagnosed multiple myeloma.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
According to the phase 2 MASTER trial, when examining the primary end point of MRD of, 38% of patients who were post induction, 65% who were post AHCT, & 80% who received MRD-directed consolidation therapy were MRD negative @ONealCancerUAB #IMW21 #mmsm https://t.co/pHg6NsyWxx https://t.co/ongJbnRYgi
-
-
Mashup Score: 0Elranatamab Alone or Plus Lenalidomide Shows Early Efficacy, Safety in Heavily Relapsed Myeloma - 3 year(s) ago
Elranatamab elicited encouraging responses with a manageable toxicity profile when used alone or in combination with lenalidomide in patients with relapsed/refractory multiple myeloma, with efficacy observed even in those who received prior BCMA-directed therapy or who were triple-class refractory, according to data from the phase 1 MagnetisMM-1 trial.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Elranatamab elicited encouraging responses w/ a manageable toxicity profile when used alone or in combination w/ lenalidomide in R/R multiple myeloma w/ efficacy observed even in those who received prior BCMA-directed therapy @DholariaMD @VUMChealth #IMW21 https://t.co/mH6GUwZ17N
-
#IMW2021 | OPTIMISMM: PVd for lenalidomide-refractory #Myeloma 📊Katja Weisel shares updates: https://t.co/NqyaP9kKqD @Myeloma_Society #IMW21 #MultipleMyeloma #MMsm #HemOnc #ImmunoOnc #CTSM #TrialUpdate